AL001

PreclinicalBiologic

AAlector Inc.

AL001 is one of 14 biologic programs targeting Bipolar I Disorder. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bipolar I DisorderRecruiting

Bipolar I DisorderPreclinical

Recruiting

Competition

Competitive Landscape

14 competitors in Bipolar I Disorder

#DrugCompanyPhaseTrials

Zyprexa

MMODAG GmbH

Approved

11 2

Risperdal

WWim Janssens

Approved

4 3

Lexapro

AbbVie

Approved

—4

Lithobid

SSolvay Pharmaceuticals

Approved

1 5

Acetadote

AArbor Pharmaceuticals, Inc.

OLZ/SAM

2 7

Endoxifen

JJina Pharmaceuticals Inc.

Phase 3

2 8

NBI-1117568

Neurocrine Biosciences

Phase 2

1 9

Icalcaprant

AbbVie

Phase 2

1 10

Treatment as Usual

AAB Biotics, SA

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalRecruiting

Bipolar I Disorder

NCT07540338

Clinical

Trials by Indication[1]

Frontotemporal Dementia3 trials

A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

Terminated·AAlector Inc.·Phase 3·NCT04374136·119 enrolled

A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation

Completed·AAlector Inc.·Phase 1·NCT03636204·64 enrolled

A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)

Completed·AAlector Inc.·Phase 2·NCT03987295·33 enrolled

Phase 21 trial

A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS

Terminated·AAlector Inc.·Phase 2·NCT05053035·5 enrolled

Alzheimer's Disease1 trial

Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects

Completed·AAlzamend Neuro, Inc.·Phase 1/2·NCT05363293·65 enrolled

Neurology1 trial

A Randomized, Balanced, Phase 1, Multiple-dose, Open-label, Two-treatment, Two-period, Two-sequence, Crossover, Relative Bioavailability Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects

Completed·AAlzamend Neuro, Inc.·Phase 1·NCT06921590·15 enrolled

Bipolar I Disorder1 trial

A Randomized, Balanced, Phase 1/2A, Multiple-dose, Open-label, Two-treatment, Two-period, Two-sequence, Crossover, Relative Bioavailability Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder

Recruiting·AAlzamend Neuro, Inc.·Preclinical·NCT07540338·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for AL001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AL001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AL001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alector Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: AAlector Inc.

AL001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Frontotemporal Dementia3 trials

Phase 21 trial

Alzheimer's Disease1 trial

Neurology1 trial

Bipolar I Disorder1 trial

References

Drug Info

Quick Facts

Related News